Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/24/2868340/0/en/Affimed-Announces-Acceptance-of-AFM24-Clinical-Abstract-at-the-2024-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html
https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html
https://www.globenewswire.com//news-release/2024/03/06/2841214/0/en/Affimed-Announces-1-for-10-Reverse-Stock-Split.html
https://www.globenewswire.com//news-release/2024/01/08/2805395/0/en/Affimed-Announces-Leadership-Change-and-Organizational-Restructuring.html
https://www.globenewswire.com//news-release/2024/01/08/2805843/0/en/Affimed-Provides-Clinical-Response-Update-on-AFM24-102-Trial-in-EGFR-wildtype-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com//news-release/2024/01/03/2803116/0/en/Affimed-Announces-Sale-of-Wholly-Owned-Subsidiary-AbCheck.html
https://www.globenewswire.com//news-release/2023/12/11/2793678/0/en/Affimed-Announces-Positive-Data-for-AFM24-in-Combination-with-the-PD-L1-Checkpoint-Inhibitor-Atezolizumab-in-Heavily-Pre-treated-EGFR-Wildtype-Non-Small-Cell-Lung-Cancer-Patients.html
https://www.globenewswire.com//news-release/2023/12/11/2793672/0/en/Affimed-Announces-Updated-Phase-1-2-Data-from-Acimtamig-in-Combination-with-Allogeneic-NK-in-Hodgkin-Lymphoma-Patients-Who-Failed-Prior-Chemotherapy-and-Are-Double-Refractory-to-Br.html
https://www.fiercebiotech.com/biotech/affimed-stops-enrolling-multiple-tumor-types-data-disappoint-forges-ahead-other-settings
https://www.globenewswire.com//news-release/2023/11/07/2774855/0/en/Affimed-to-Report-Third-Quarter-2023-Financial-Results-Corporate-Update-on-November-14-2023.html